Adoptive immunotherapy of cancer using chimeric antigen receptor (CAR)-engineered T cells with redirected specificity showed efficacy in recent trials. In preclinical models, 'second-generation' CARs with CD28 costimulatory domain in addition to CD3z performed superior in redirecting T-cell effector functions and survival. Whereas CD28 costimulation sustains physiological T-cell receptor (TCR)-CD3 activation of naïve T cells, the impact of CD28 cosignalling on the threshold of CAR-mediated activation of pre-stimulated T cells without B7-CD28 recruitment remained unclear. Using CARs of different binding affinities, but same epitope specificity, we demonstrate that CD28 cosignalling neither lowered the antigen threshold nor the binding affinity for redirected T-cell activation. 'Affinity ceiling' above which increase in affinity does not increase T-cell activation was not altered. Accordingly, redirected tumor cell killing depended on the binding affinity but was likewise effective for CD3z and CD28-CD3z CARs. In contrast to CD3z, CD28-CD3z CAR-driven activation was not increased further by CD28-B7 engagement. However, CD28 cosignalling, which is required for interleukin-2 induction could not be replaced by high-affinity CD3z CAR binding or high-density antigen engagement. We conclude that CD28 CAR cosignalling does not alter the activation threshold but redirects T-cell effector functions.
INTRODUCTION
For use in adoptive immunotherapy, T cells can be redirected with predefined specificity by engineering with chimeric antigen receptors (CARs) that consist of an antibody-derived binding domain in the extracellular and a T-cell activation domain in the intracellular moiety. 1 The binding domain consists of a single-chain fragment of variable region (scFv) antibody linked either directly or through an extracellular spacer to the intracellular CD3z chain. Although CD3z signalling alone is sufficient to initiate redirected activation of prestimulated T cells, 2, 3 an additional costimulatory signal is required for full T-cell activation, prevention from activation-induced cell death and anergy. CD28 is the prototype of a family of costimulatory molecules that is physiologically engaged by binding to ligands on antigen-presenting cells (APCs). However, most therapeutically targeted cells, including tumor cells, do not express the CD28-activating ligands B7.1 (CD80) or B7.2 (CD86) that are physiologically expressed on APCs. To provide appropriate costimulation, the intracellular CD3z chain was covalently linked to the costimulatory domain of CD28 or to other members of the CD28 family including 4-1BB (CD137) and OX40 (CD134) in the same CAR molecule. [4] [5] [6] [7] [8] This 'second-generation' CAR has the advantage that redirected T-cell activation is accompanied by suppressing inhibitory and/or strengthening stimulatory signals. Accordingly, Beecham et al. 9 demonstrated that CD28 costimulation sustains survival and prolonged polyclonal expansion of CAR-engineered T cells. CAR-mediated CD28 cosignalling induces interleukin-2 (IL-2) that is used in an autocrine fashion by redirected T cells to increase their amplification without the need of B7-CD28 engagement. 7 CD28-CD3z CAR signalling moreover counteracts transforming growth factor-b1-mediated repression in T-cell proliferation. 10 Both sustained survival and increased amplification result in a prolonged redirected T-cell response and in an improved antitumor attack, making second-generation CARs favorable for clinical use. [11] [12] [13] In physiological activation of naïve T cells, CD28 recruitment by B7 engagement sustains formation of the immunological synapse, thereby lowering the antigen threshold and increasing T-cell activation. In physiological T-cell activation, the activation efficiency correlates with the T-cell receptor (TCR) avidity to the cognate peptide-major histocompatibility complex (MHC) complex. [14] [15] [16] [17] [18] Optimal CD28 costimulation is provided by high-avidity engagement by dimeric B7.1 expressed on APCs, followed by dimer dissociation that facilitates downregulaton of CD28 and B7.1 internalization. 19 CD28 costimulation induces at least two independent activation pathways: one is integrated with TCR signalling in the context of synapse formation and is mediated through transcriptional enhancement and the second is mediated through increasing mRNA stability. 20 CD28-CD3z CARredirected T-cell activation, however, differs from physiological TCR-CD28 activation in so far that the CAR delivers the costimulatory signal independently of B7 recruitment to the triggering synapse. Although CD3z CAR-mediated T-cell activation strongly depends on the affinity of the antibody-derived binding domain, 21 it remains unclear whether CD28 cosignalling in second-generation CARs without B7 recruitment alters the affinity-dependent threshold in redirected T-cell activation. The issue is of major relevance with respect to the fact that most target antigens for redirected adoptive immunotherapy are not exclusively expressed on tumor cells but broadly on a variety of healthy tissues, although at lower levels. A lower activation threshold because of CAR CD28 cosignalling would negatively impact the selectivity of a redirected T-cell attack.
To address the impact of CD28 cosignalling, we redirected human peripheral blood T cells toward ErbB2 (Her2/neu) by CD28-CD3z and CD3z signalling CARs, respectively, both sets with different binding affinities but the same epitope specificity. Data revealed that CD28 cosignalling does not impact the activation threshold or 'affinity ceiling' , above which an increase in affinity does not increase T-cell activation but T-cell-mediated effector functions. CD28 costimulatory CARs can increase cytokine secretion, but cannot increase sensitivity toward target cells expressing intermediate or low ErbB2 densities. Moreover, CD28 costimulation, which is required for IL-2 secretion, cannot be replaced by high-affinity binding or high antigen densities in the presence of a CD3z CAR. This is of major relevance for the adoptive immunotherapy of cancer, as lowering the affinity ceiling and antigen-dependent threshold of CAR-redirected T cells would have made healthy cells expressing low levels of antigen potential targets for T-cell attack, resulting in autoimmunity.
RESULTS
The second-generation CARs with intracellular CD3z fused to the CD28 costimulatory domain simultaneously deliver CD3z and CD28 signalling on antigen engagement. We addressed whether CD28 cosignalling impacts the affinity threshold of CAR-driven T-cell activation. We made use of a panel of scFvs targeting the same ErbB2 epitope with different affinities, that is, (Table 1) . Two sets of CARs with either CD3z or combined CD28-CD3z signalling domains were generated ( Figure 1a ) and retrovirally expressed human peripheral blood T cells (Figure 1b ). Cells were pre-activated through CD3-IL-2 in order to allow retroviral transduction.
To confirm the redirected specificity of CAR-mediated activation, T cells genetically engineered with CARs of different specificities, that is, for ErbB2 and CD30, respectively, were coincubated with the respective target cells, that is, SK-OV-3 cells of ErbB2 + CD30 -and MyLa cells of ErbB2 -CD30 + phenotype (Figure 2a ). Anti-ErbB2 CARengineered T cells were activated by SK-OV-3, but not by MyLa cells, indicated by dose-dependent increase in interferon-g (IFN-g) secretion and lysis of SK-OV-3 cells, whereas MyLa cells were not lysed (Figure 2b ). Vice versa, T cells with the anti-CD30 CAR were activated by MyLa, but not by SK-OV-3 cells.
To address the affinity-dependent T-cell activation in the presence of CD28 cosignalling, T cells were engineered with the panel of anti-ErbB2 CARs of different affinities, each triggering through the CD3z and the combined CD28-CD3z domains, respectively. On coincubation with ErbB2 high SK-OV-3 cells, IFN-g secretion was substantially enhanced in T cells with CD3z-CD28 cosignalling CAR compared with CD3z-only CAR (Figure 3a) . Increase in binding affinity above K d ¼1.6Â10 À8 M, however, did not further increase IFN-g secretion. 'Affinity ceiling' was found for both CD3z and CD28-CD3z CAR-redirected T-cell activation; noteworthy, the 'ceiling affinity' was the same for CD3z and CD28-CD3z signalling CARs, as summarized in Figure 3b .
To address the impact of CD28 cosignalling on T-cell-mediated cytolysis, the viability of SK-OV-3 target cells was monitored in the presence of engineered cytolytic T cells. T cells triggered by CARs with higher binding affinities, that is, K d o10 À8 M, lysed SK-OV-3 cells in a similar fashion, whereas T cells triggered by the low-affinity CAR executed cytolysis with lower efficiency (Figure 3a) . However, the cytolytic efficacy was not substantially affected by CD28 costimulation.
CD28-CD3z CAR-triggered T-cell activation was accompanied by IL-2 secretion that was not recorded on CD3z CAR signalling, even not on high-affinity binding (Figure 3a) . We conclude that highaffinity binding of CD3z CARs does not substitute for CD28 costimulation with respect to the induction of IL-2 secretion. High-affinity binding in the presence of CD28 cosignalling, however, did not further increase the amount of secreted IL-2. 'Affinity ceiling' occurred at the same threshold as observed for the induction of IFN-g secretion, that is, K d ¼10 À8 M. Taken together (Figure 3b ), the data demonstrate that inclusion of the CD28 cosignalling domain, although necessary for induction of IL-2, enhanced IFN-g release but did not substantially affect cytotoxicity. Noteworthy, CD28 did not alter the affinity threshold or 'affinity ceiling' in redirected T-cell activation compared with CD3z signalling only.
To rule out whether the altered CD3z position in the CD28-CD3z CAR compared with the CD3z CAR is responsible for IL-2 induction, we replaced the CD28 by the intracellular CD8 domain of same length. In contrast to CD28-CD3z CAR, CD8-CD3z CAR-redirected T cells did not produce IL-2 on engagement of ErbB2 + SK-OV-3 cells (Figure 4 ). The data indicate that CD28 cosignalling, and not the more membrane distal position of CD3z, is responsible for the induction of IL-2 secretion. Our conclusion is confirmed by the observation that T cells triggered by the mutated CD28D-CD3z CAR, in which the Lck-binding motif is deleted by two-point mutations, showed no IL-2 secretion, whereas IFN-g secretion was not substantially altered (data not shown). Table 1 Characteristics of the anti-ErbB2 scFvs (Adams 22 ) used as binding domains in this study 
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In addition to the affinity, the amount of antigen has substantial impact on redirected T-cell activation, which may be affected by CD28 CAR cosignalling. On engineering with anti-ErbB2 CARs with or without CD28 and with high-or low-binding affinity, respectively, T cells were incubated on plates coated with increasing amounts of ErbB2. T cells triggered by high-affinity CARs required lower antigen amounts to induce IFN-g compared with T cells with low-affinity CARs (Figure 5a ). T cells with CD28-CD3z CARs, however, required the same antigen amount for activation as T cells with CD3z CARs, indicating that CD28 costimulation has no substantial impact on the antigen threshold for redirected T-cell activation.
To (Figure 5c ), the data indicate that there is a clear correlation between binding affinity and the amount of antigen required to induce T-cell activation. CD28 cosignalling, however, does not impact the antigen threshold required to initiate T-cell activation, independently of whether T cells engage antigen through high-or low-affinity binding. IL-2 induction required CD28 cosignalling that cannot be substituted by high-affinity binding or high amounts of antigen.
As CD28-CD3z signalling CARs bypass the requirement to recruit CD28-B7 complexes into the triggering synapse, we asked whether physical cell-cell interactions through B7-CD28 have additional impact on CAR-redirected T-cell activation. ErbB2 + LS174T tumor cells were engineered with B7-1 and B7-2 ( Figure 6a ). T cells were engineered with the CD3z or CD28-CD3z CAR, respectively (Figure 6b ), and coincubated either with ErbB2 + B7 À LS174T or CD28 cosignalling in redirected T-cell activation M Chmielewski et al with engineered ErbB2 + B7-1 + B7-2 + LS174T cells. CD3z CAR-driven T-cell activation was increased on binding to B7 + LS174T cells compared with LS174T lacking B7; however, CD28-CD3z CAR-driven T-cell activation, was not increased further ( Figure 6c ). The data indicate that additional B7-CD28 engagement has impact on CD3z CAR, but not on CD28-CD3z CAR-triggered T-cell activation.
To explore the cytolytic activity of CD3z and CD28-CD3z CARredirected T cells, we engineered T cells with CARs of high and low affinity (K d ¼1.5Â10 À11 and 3.2Â10 À7 M, respectively), both with CD3z and CD28-CD3z signalling domains, respectively. ErbB2 + tumors were induced in Rag-2 -/-cg -/-mice by subcutaneous transplantation of LS174T tumor cells. When tumors were established to a size of approximately 40-60 mm 3 , engineered T cells were peritumorally applied in order to make sure that the same number of engineered T cells are in or near the tumor lesion. As shown in Figure 7 , tumor growth was more efficiently repressed by high-affinity than by low-affinity CAR T cells. The same performance, however, was found for CD3z and CD28-CD3z CAR-redirected T cells; in particular, the redirected tumor cytolytic response by the low-affinity CAR was not increased by CD28 costimulation. This is in accordance to our observation that the cytolytic capacity of redirected T cells in vitro was not altered by CD28 costimulation (cf Figure 3a) . Although this experimental outline excludes secondary factors like T-cell persistence, migration, proliferation and prevention of activation-induced cell death in recording T-cell-mediated tumor cell lysis, the long-term efficacy of an antitumor response is dependent on these factors and substantially modulated by CD28 costimulation. 23, 24 
DISCUSSION
In the adoptive immunotherapy of cancer, second-generation costimulatory CARs are currently entering clinical trials; however, the impact of CD28 cosignalling without B7 engagement on the threshold in CAR-redirected T-cell activation was so far little explored. Although B7-CD28 engagement lowers the threshold in physiological TCR-CD3 activation of naive T cells, we here revealed that CD28 cosignalling by a chimeric antigen receptor does not affect the antigen and affinity-dependent threshold in T-cell activation. This is particularly obvious in the situation of low-affinity antigen binding and of binding to low amounts of antigen. Our data are based on a panel of CARs targeting the same epitope of ErbB2 with different affinities, that is, from 3.2Â10 À7 to 1.5Â10 À11 M. Redirected T-cell activation is more efficient by higher than by low-affinity binding; however, there is an 'affinity ceiling' of approximately 10 À8 M, at least in our example of anti-ErbB2 CARs, above which increase in affinity does not increase redirected T-cell activation. We previously reported 'affinity ceiling' for CD3z CAR-redirected T cells at the same affinity; 21 therefore, it was unexpected that CD28 does not substantially impact the binding affinity-dependent T-cell activation. The observation has substantial consequences for the redirected immunotherapy of cancer, as a number of tumor-associated antigens used for redirected targeting are also expressed in healthy tissues, although at lower levels. A lower activation threshold due to CD28 cosignalling would have negatively impacted the selectivity of a CAR-redirected T-cell attack and increased the risk of autoimmunity. In vitro data were confirmed by CAR-redirected tumor cytolysis in vivo that was dependent on the binding affinity and not altered by CD28 costimulation (cf Figure 7) . Although we here recorded short-term tumor cytolysis after administration of engineered T cells in the vicinity of the tumor, secondary parameters additionally impact the overall outcome in a long-term anti-tumor attack compared with CD3z CAR-driven T-cell activation. For instance, CD28 costimulation increases the expression of B-cell lymphoma 2 protein, preventing activation-induced cell death and anergy and thereby improving the long-term antitumor attack. 25 CD28 cosignalling impacts the cytokine response of redirected T cells. IFN-g is increased and IL-2 secretion is induced by CD28 cosignalling. 6, 26 The altered pattern in cytokine secretion in the presence of CD28 cosignalling is not due to an altered CD3z activity as a consequence of the more distal membrane position in the CD28-CD3z CAR, as the CD8-CD3z CAR, which harbors the CD8 In accordance with our data, Willemsen et al. 27 previously reported that engagement of a MHC class I-restricted CAR with g signalling domain increased cytokine secretion when combined with CD28 costimulation. A CAR targeting the same antigen with higher affinity showed increased cytokine secretion. Cytolysis by g-CD28 CAR-modified T cells was improved compared with g CAR T cells when target cells were loaded with small amounts of peptide antigen. Increasing antigen amounts, however, decreased the difference in cytolytic activities of g versus g-CD28 CAR T cells, in particular of the high-affinity CAR. Compared with MHC-loaded peptide antigen, the MHC-independently targeted antigen in our study is present in substantially higher amounts on the cell surface, which may explain the difference in the observations. In addition to the binding affinity, the position of targeted epitope within the cognate antigen has major impact on the efficacy of 
IFN-γ γ

CD28 cosignalling in redirected T-cell activation M Chmielewski et al
CAR-driven T-cell activation. 28 We previously explored the situation by redirecting T cells against the membrane distal and the proximal domain of carcinoembryonic antigen. The membrane-proximal carcinoembryonic antigen epitope more efficiently mediates CARredirected T-cell activation than the distal epitope. Targeting the distal epitope in a more membrane-proximal position in a modified carcinoembryonic antigen molecule, however, increased activation of engineered T cells. We conclude that the epitope position within the targeted molecule, in addition to the binding affinity, has an impact on the efficacy of T-cell activation. Although a CD28-CD3z CAR provides CD28 cosignalling in the absence of B7-CD28 recruitment, additional CD28-B7 engagement did not further alter T-cell activation. In the presence of a CD3z CAR, however, B7 engagement increased IFN-g secretion of redirected T cells, indicating that the physiological CD28 costimulation cooperates with CAR-driven T-cell activation. There are, however, several differences in the TCR-CD28 and CAR-driven T-cell activation. The avidity of physiological TCR-MHC interactions is much lower than those of the antibody domains used in CAR binding. Another caveat is the activation of naïve T cells, whereas CAR-modified T cells are pre-stimulated to allow retroviral engineering. On physiological T-cell-APC interactions, CD28-B7 binding potentates synapse formation by increasing TCR-CD3 density through approximation of the interacting membranes. [29] [30] [31] [32] Signal amplification through receptor clustering results in the integration of the TCR with costimulatory signalling that becomes obvious when compensating for a weak TCR signal. 33 Early events in T-cell activation are likely to require B7-CD28 engagement that helps to form the synapse, with the result that lowaffinity ligands can also successfully initiate T-cell signalling. 32 This implies that in low-avidity, T cell induction of T-cell activation is dependent on the extent of supramolecular clustering. The TCR binding threshold exhibits a relatively sharp cutoff between full activity and no activity that seems to be marginally modulated by CD8. Moreover, the peptide-MHC has to be presented in a form that allows the appropriate synapse formation on the T cell in order to initiate downstream signalling including IL-2 release. 15 Costimulatory molecules are thought to increase stability during early stages in this process. Optimal CD28 costimulation requires high-avidity CD28 cosignalling in redirected T-cell activation M Chmielewski et al engagement by dimeric B7.1 on APCs, followed by dimer dissociation that facilitates CD28 downregulation and B7.1 internalization. 19 TCR and CD28 costimulation downmodulates the TCR-induced cyclic AMP-mediated inhibitory signals through recruitment of a b-arrestin-phosphodiesterase 4 complex, leading to cyclic AMP degradation and thus allowing a full T-cell response to occur. 34 In contrast to physiological TCR-CD28, the CD28-CD3z CAR drives T-cell activation independently of CD28 recruitment into the triggering synapse and provides CD28 cosignalling without the need of B7.1 engagement. The artificial fusion of the CD28 and CD3z signalling 
MATERIALS AND METHODS
Cell lines and reagents
293T cells are human embryonic kidney cells that express the SV40 large T antigen. 35 SK-OV-3 (ATCC (American Type Culture Collection) HTB77, Manassas, VA, USA), LS174T (ATCC CL 188) 36 and Colo320 (ATCC CCL 220.1) are derived from various adenocarcinomas expressing different amounts of ErbB2. LS174T-B7 cells were obtained by transfection of LS174T cells with an expression vector for both B7-1 and B7-2. 6 MyLa are CD30 + ErbB2 À cutaneous lymphoma cells kindly provided by Dr K Kaltoft (University of Aarhus, Denmark). The MC38 murine tumor cell line was kindly provided by Dr M Neumaier (University Hospital Eppendorf, Hamburg, Germany) and transfected to express human ErbB2. OKT3 (ATCC CRL 8001) is a hybridoma cell line that produces the anti-CD3 monoclonal antibody OKT3. 293T cells were cultured in Dulbecco's modied Eagle's medium supplemented with 10% (v/v) fetal calf serum; all other cell lines were cultured in RPMI-1640 medium, 10% (v/v) fetal calf serum (all from Life Technologies, Paisly, UK). OKT3 antibody was affinity purified from hybridoma supernatants utilizing goat antimouse IgG2a antibodies (Southern Biotech, Birmingham, AL, USA) that were immobilized on N-hydroxy-succinimid-ester-activated sepharose as recommended by the manufacturer (Amersham Biosciences, Freiburg, Germany). C6-B1D2scfv-hIgG fusion protein was affinity purified from supernatants of transfected 293T cells utilizing the human IgG1-specific monoclonal antibody 4E3 (Southern Biotech) that has been immobilized on N-hydroxy-succinimidactivated sepharose (Amersham Biosciences). The phycoerythrin (PE)-conjugated anti-human CD3 antibody UCHT1 was purchased from Dako (Hamburg, Germany). The PE-conjugated goat anti-human IgG antibody F(antibody') 2 and the PE-conjugated goat anti-mouse IgG polyclonal sera were purchased from Southern Biotechnology. The mouse anti-human ErbB2 antibody Antibody-5 was purchased from Oncogene (Cambridge, MA, USA), the recombinant ErbB2-IgG Fc fusion protein from R&D Systems (Minneapolis, MN, USA) and the PE-conjugated mouse anti-human CD30 antibody Ber-H2 from Dako. The anti-human IFN-g antibody NIB42, the biotinylated antihuman IFN-g antibody 4S.B3, the anti-human IL-2 antibody 5344-111 and the biotinylated anti-human IL-2 antibody B33-2 were purchased from BD Bioscience (San Jose, CA, USA). The generation of the anti-ErbB2 scFv antibodies has been described in detail. 37 The binding parameters of the anti-ErbB2 scFvs are summarized in Table 1 .
Generation of CD8 cDNA mRNA was prepared from T cells using 'RNeasy Mini Kit' following the manufacturer's instructions, and first-strand complementary DNA (cDNA) was synthesized using 'Oligo-dT and Omniscript RT Kit' (all from Qiagen, GmbH, Hilden, Germany). The CD8 cDNA was synthesized by PCR amplification using the primer oligonucleotides, 5¢-ANTIGENCGATGGATCCATCTA CATCTGGGCGCCCTTGGCC-3¢ (sense) and 5¢-GTCTGCGCTCCTGCTG AACTTCACTCTGACGTATCTCGCCGAAANTIGENGCTGGGCTT-3¢ (antisense), thereby incorporating the BamHI restriction site.
Generation of recombinant CARs
The generation of the ErbB2-specific anti-ErbB2-scFv-Fc-CD3z CARs with the CD3z signalling domain has been described in detail. 21 To generate the retroviral expression cassettes for the anti-ErbB2-scFv-Fc-CD28-CD3z CARs with combined CD28-CD3z signalling domain, the C6.5 scFv DNA and its derivatives (kindly provided by Dr J Marks, UCSF) ( Table 1) were amplified by PCR using the following set of primer oligonucleotides (NcoI and BamHI restriction sites are underlined): 5¢-CGTACCATGGATTTTGANTIGENGT GCANTIGENATTTTCANTIGENCTTCCTGCTAATCANTIGENTGCCTCAGT CATAATGTCTANTIGENACCGGCGATGGCCCANTIGENGTG-3¢ (sense) and 5¢-TTCTGGATCCGCACCTANTIGENGACGGTGACCTT-3¢ (antisense). The amplified anti-ErbB2 scFv DNA replaced the scFv DNA of the BW431/ 26scFv-Fc-CD28-CD3z CAR, which was previously described. 6 To generate CD8-containing CARs, the CD8 cDNA was assembled together with the intracellular CD3z cDNA and amplified by PCR using the primer oligonucleotides, 5¢-ANTIGENCGATGGATCCATCTACATCTGGGCGCCCTTGGCC-3¢ (sense) and 5¢-TATCTTCTCGANTIGENTTAGCGANTIGENGGGGCANTI-GENGGCCTGC-3¢ (antisense), thereby incorporating the BamHI and XhoI restriction site, respectively (underlined). The amplified PCR product CD8-CD3z was excised with BamHI and XhoI and cloned between the BamHI and XhoI sites of the anti-ErbB2 CAR encoding vectors. 21 T cells were transduced with recombinant retroviruses as described in detail elsewhere. 35 Cells were analyzed by flow cytometry. Tumor repression by engineered T cells depends on the binding affinity and is not altered by CD28 costimulation. ErbB2-transfected MC38 tumor cells were subcutaneously injected (0.8Â10 6 tumor cells per mouse) into Rag-2 À / À gc À / À mice (six mice per group). Tumors were grown to a size of 40-60 mm 3 . T cells (2Â10 6 ) with ErbB2-specific CARs of different affinities (1.5Â10 À11 and 3.2Â10 À7 M, respectively) and with CD28-CD3z and CD3z domains, respectively, were peritumorally injected at day 0. Tumor progression was daily monitored for up to 40 days. Tumor volumes were compared using one-tailed t-test. 
CAR-mediated activation of engineered T cells
T cells were engineered by retroviral gene transfer with ErbB2-specific CARs containing the CD28-CD3z and the CD3z signalling domains, respectively, and 0.078Â10 4 -1Â10 4 CAR-expressing T cells per well were cocultivated with target cells (5Â10 4 cells per well). The culture supernatants were analyzed for IFN-g by enzyme-linked immunosorbent assay. Briefly, IFN-g was bound to the solidphase anti-human IFN-g antibody NIB42 (1 mg ml -1 ) and detected by the biotinylated anti-human IFN-g antibody 4S.B3 (0.5 mg ml -1 ) (BD Bioscience). The reaction product was visualized by a peroxidase-streptavidin conjugate (1:10 000) and ABTS as substrate. IL-2 in the culture supernatant was measured using enzyme-linked immunosorbent assay. Briefly, IL-2 was bound to the solid-phase coated anti-human IL-2 antibody 5344-111 and detected by the biotin-conjugated anti-human IL-2 antibody B33-2 (0.5 mg ml -1 ) (BD Bioscience). Specific cytotoxicity was monitored by an XTT (2,3-bis (2-methoxy-4-nitro-5sulphonyl)-5((phenyl-amino)carbonyl)-2H-tetrazolium hydroxide) reagent-based colorimetric assay, according to Jost. 38 Briefly, engineered and mock-transduced T cells were cocultivated with ErbB2 + or ErbB2 -tumor cells. After 48 h, XTT (1 mg ml -1 ) (Cell Proliferation Kit II; Roche Diagnostics, GmbH, Mannheim, Germany) was added and incubated for 30 to 90 min at 37 1C. 
Mice
The Rag-2 À / À gc À / À mice were obtained from Dr D von Laer (Applied Virology and Gene Therapy, Georg-Speyer-Haus, Frankfurt/Main, Germany). To test for tumor growth, cells of the ErbB2 + subclone MC38/ErbB2 were subcutaneously injected into Rag-2 À / À gc -/ À mice (0.8Â10 6 tumor cells/mouse; six mice per group) and grown to volumes of approximately 40-60 mm 3 . Engineered T cells with ErbB2-specific CAR were once intratumorally injected (2Â10 6 T cells per mouse). Tumor progression was monitored for 40 days after treatment. We confirm that all experiments were performed in accordance with relevant guidelines and regulations.
